Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients.
During 6 months of treatment, we measured human immunodeficiency virus (HIV)-1 virus loads, CD4 T cell counts, and immune activation markers, in 111 HIV-1-infected patients with active tuberculosis (TB). The median virus load (baseline, 5.58 log(10) copies/mL) significantly increased at 1 month (5.71 log(10) copies/mL), then returned to near-baseline levels at 3 months (5.40 log(10) copies/mL) and at 6 months (5.36 log(10) copies/mL). In contrast, the median CD4 counts increased at 1 month (186/mm(3)), at 3 months (238/mm(3)), and at 6 months (239/mm(3)). CD4 counts and virus loads did not change during therapy. Expression of CD38 and HLA-DR remained high throughout treatment, whereas plasma levels of interleukin-6 decreased over time.
Morris
Lynn
L
AIDS Virus Research Unit, National Institute for Communicable Diseases, Sandringham, Johannesburg, South Africa.
Martin
Desmond J
DJ
Bredell
Helba
H
Nyoka
Stephina N
SN
Sacks
Leonard
L
Pendle
Stella
S
Page-Shipp
Liesl
L
Karp
Christopher L
CL
Sterling
Timothy R
TR
Quinn
Thomas C
TC
Chaisson
Richard E
RE
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D015658:HIV Infections / Q000150:complications* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification*; D006801:Humans; D009169:Mycobacterium tuberculosis; D012367:RNA, Viral / Q000032:analysis*; D013019:South Africa; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D019562:Viral Load
D000995:Antitubercular Agents; D012367:RNA, Viral